Wall Street analyst estimates for Amylyx Pharmaceuticals, Inc. (AMLX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor.
Consensus price target
$52.20 (+79% vs price $29.20)
between $42.00 and $57.00 · 9 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $80,625 | $25,153 – $162,514 | -$1.50 | 7 |
| 2027E | $56.5M | $22.2M – $90.9M | -$1.13 | 7 |
| 2028E | $211M | $68.3M – $444M | -$0.19 | 6 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (−2 sell to +2 buy) | 0.91 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.38 | ||
| 2026-08-06 | $-0.39 | $-0.36 | -8.1% |
| 2026-05-07 | $-0.37 | $-0.34 | -8.8% |
| 2026-03-03 | $-0.30 | $-0.31 | +3.2% |
| 2025-11-06 | $-0.37 | $-0.43 | +14.0% |
| 2025-08-07 | $-0.46 | $-0.44 | -4.5% |
| 2025-05-08 | $-0.42 | $-0.45 | +6.7% |
| 2025-03-04 | $-0.55 | $-0.49 | -12.2% |
Valuation Ratios
| Price / Book | 13.58 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $650,000 | 0 | $22.2M | $380.8M | $87.4M | 0 |
| Cost of Revenue | $11.9M | $24.6M | 0 | $3.0M | $25.4M | $42.2M | $525,000 |
| Gross Profit | -$10.5M | -$23.9M | 0 | $19.2M | $355.3M | $45.2M | -$525,000 |
| Research & Development | $11.9M | $24.6M | $44.0M | $93.5M | $128.2M | $104.1M | $90.4M |
| Selling, General & Admin | $3.1M | $15.1M | $38.9M | $127.1M | $188.4M | $114.3M | $62.9M |
| Operating Expenses | $13.6M | $15.1M | $82.7M | $220.6M | $316.5M | $359.9M | $152.8M |
| Operating Income | -$13.6M | -$39.0M | -$82.7M | -$201.3M | $38.8M | -$314.7M | -$153.3M |
| EBITDA | $1.1M | -$39.0M | -$87.9M | -$197.1M | $55.4M | -$291.0M | -$144.2M |
| Interest Expense | $1.3M | $2.3M | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$13.7M | -$42.3M | -$87.9M | -$197.6M | $54.3M | -$302.1M | -$144.7M |
| Income Tax | 0 | 0 | 0 | $774,000 | $5.0M | -$393,000 | $46,000 |
| Net Income | -$14.8M | -$42.3M | -$87.9M | -$198.4M | $49.3M | -$301.7M | -$144.7M |
| EPS | -$0.26 | -$0.79 | -$1.52 | -$2.98 | $0.73 | -$4.43 | -$1.53 |
| EPS (Diluted) | -$0.26 | -$0.79 | -$1.52 | -$2.98 | $0.70 | -$4.43 | -$1.53 |
| Shares Outstanding (Diluted) | 56.5 M | 56.5 M | 57.9 M | 66.5 M | 70.0 M | 68.1 M | 94.6 M |
Price
| Price | $29.20 (closing price, November 3, 2026) |
| Market Cap | $3.7B |
| Exchange | NASDAQ |
| Country | US |
Related companies: IONS · PRAX · DNLI · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of AMLX: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks